Bicycle Therapeutics plc
BCYC
$9.69
$0.060.62%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 38.57% | -71.41% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 38.57% | -71.41% | |||
| Cost of Revenue | -233.24% | 19.19% | |||
| Gross Profit | 258.80% | -48.49% | |||
| SG&A Expenses | -26.71% | 17.88% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.29% | 18.77% | |||
| Operating Income | -5.98% | -36.87% | |||
| Income Before Tax | 2.42% | -36.66% | |||
| Income Tax Expenses | 68.62% | -3,098.26% | |||
| Earnings from Continuing Operations | -2.07% | -27.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.07% | -27.60% | |||
| EBIT | -5.98% | -36.87% | |||
| EBITDA | -6.95% | -37.03% | |||
| EPS Basic | -1.97% | 3.83% | |||
| Normalized Basic EPS | -7.62% | -1.17% | |||
| EPS Diluted | -1.97% | 3.83% | |||
| Normalized Diluted EPS | -7.62% | -1.17% | |||
| Average Basic Shares Outstanding | 0.09% | 32.69% | |||
| Average Diluted Shares Outstanding | 0.09% | 32.69% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
